The 10-year Treasury reached 5.20% overnight and was 5.186% at 00:07 ET, up 2.4 bp from Thursday's close; the 2-year eased 0.4 bp to 4.891%. The bear-steepening keeps the discount-rate shock active even as equity futures rise. CNBC 10Y · CNBC 2Y
WTI fell about 1.9% to $92.84 after Thursday's $94.61 settlement as markets weighed reports that U.S. and Iranian negotiators were considering a phased deal involving the Strait of Hormuz. Negotiations are not a signed settlement; energy inflation remains a live tail risk. CNBC close/report · CNN live markets
IONQ gained 5.74% on nearly 2× 20-day volume after two customer/deployment announcements, while ANET gained 1.10% and LLY 2.68%. AVGO, VRT and NVDA fell despite a flat Nasdaq. This is stock selection, not broad risk-on confirmation. IonQ–FIU · Yahoo Markets
| Asset | Level | Move | Session / timestamp | Read-through |
|---|---|---|---|---|
| S&P 500 / Nasdaq | 7,704.13 / 26,939.37 | −0.02% / +0.01% | Thursday U.S. close | Flat headline indexes concealed cyclicals/rate pressure. |
| Dow / Russell 2000 | 51,349.98 / 2,835.57 | −0.31% / −0.11% | Thursday close | Dow posted a third daily decline; small caps remain weak. |
| VIX | 15.67 | +3.23% | Thursday close | Stress rising but far from capitulation. |
| ES / NQ / YM / RTY futures | 7,777.8 / 30,902 / 51,786 / 2,863.9 | +0.14% / +0.44% / +0.13% / +0.25% | ~08:18 CEST, Yahoo/CNN | Modest relief; NQ leads but rates do not validate it. |
| U.S. 2Y / 10Y | 4.891% / 5.186% | −0.4 bp / +2.4 bp | CNBC Tradeweb, 08:30 / 06:07 CEST | Curve steepens; 10Y touched 5.20%, a fresh 52-week high. |
| DXY / WTI / Gold | 101.13 / $92.84 / $4,314.80 | −0.15% / −1.87% / +0.39% | Yahoo futures, 08:18 CEST | Oil respite helps; gold resilience still signals macro hedging. |
| Nikkei / Hang Seng | 66,329 / 24,431 | +1.22% / −1.34% | Nikkei close; Hong Kong live ~08:18 CEST | Japan strength contrasts with China/HK weakness. |
| Shanghai Composite | 3,888.37 | −1.22% | Latest available: Thursday close | Friday observation unavailable in Yahoo feed at cutoff; not treated as live. |
| STOXX 600 / DAX / FTSE / MIB | 636.43 / 25,266.53 / 10,679.99 / 51,543.45 | −0.55% / −0.57% / −0.24% / −0.85% | Thursday close; Friday cash pre-open | Europe opens 09:00 Italy; these are not Friday indications. |
Prices: Yahoo chart API retrieved 08:18 CEST, cross-checked against CNN and Markets Insider. Treasury yields: CNBC/Tradeweb. Futures and commodities use provider-specific session/settlement conventions and may be delayed. At 08:30 Italy, European cash markets had not opened and scheduled U.S. releases were hours away.
No compelling new bullish entry at the 08:30 cutoff. Positive futures do not clear the 5.20% 10Y risk. The only ranked actions are tactical avoids; none is a borrow or short recommendation. Initial two weeks remain paper-tracking. Confidence scores evidence quality, not success probability; Risk is higher when more dangerous.
NASDAQ · Small-cap clinical biotech · Extreme risk · Classification: avoid/new-long pause, not short · Horizon: day and 1–4 weeks · Direction uncertain/gap-prone
Thesis/catalyst: $35 equity pricing below Thursday's $36.75 close plus $225m of converts creates supply and hedging overhang after a 5.99×-volume selloff. Evidence: primary pricing release and market tape. Counterargument: $500m base proceeds materially strengthen runway, while VK2735 maintenance data support a potentially differentiated asset.
NYSE ADR / Copenhagen · Large-cap pharma · High risk · Classification: avoid, not short · Horizon: day and 1–4 weeks · Direction highly uncertain
Thesis: $38.62 is 11.2% below its 20-day and 16.1% below 50-day average despite Thursday's bounce; relative trend remains weak. Evidence: consecutive Yahoo closes through Sept. 24. Counterargument: depressed expectations, approved oral Wegovy and Q4 CagriSema regulatory action can drive a violent reversal.
NYSE · Large-cap data-center power/cooling · High risk · Classification: avoid new entry, not short · Horizon: day and 1–4 weeks · Long-term direction uncertain-positive
Thesis: $245.30 (−1.40%) is below 20D $255.85 and 50D $267.78 while long yields rise; relative weakness persists despite AI demand. Evidence: daily price series through Sept. 24. Counterargument: structural liquid-cooling and power demand can produce sharp rebounds when rates stabilize.
| Rank / classification | Exchange, risk & horizon | Thesis, catalyst, evidence & counterargument | Entry / invalidation / downside / key risks | Confidence / Risk / Opportunity |
|---|---|---|---|---|
| 1 ANET Bullish watch | NYSE · Large-cap networking · High risk Day / 1–4 weeks / 3–12+ months; uncertain positive | $205.70, +1.10%; above 20D $196.16 and 50D $188.81. AI Ethernet is the catalyst. Counter: 5.2% 10Y, customer concentration and modest 0.71× volume. | Confirm above $207 with volume/SOX breadth; close below $198 weakens, below $190 invalidates tactical case. Risks: capex, competition, valuation, exports, concentration. | 78 / 74 / 73 |
| 2 LLY Clinical watch | NYSE · Mega-cap pharma · Med/high risk 1–4 weeks / 3–12+ months; uncertain positive | $1,181.89, +2.68%; retatrutide EASD detail Sept. 30. Phase 3 TRIUMPH-2 met primary endpoint. Counter: valuation, dose-related GI/dysesthesia and no approval yet. | Require hold $1,175 or post-data higher low; below $1,145 weakens, $1,120 invalidates swing. Demand CIs, estimands, discontinuation and safety detail. Access/manufacturing/FDA risk. | 89 / 72 / 78 |
| 3 NVDA Quality AI watch | NASDAQ · Mega-cap semiconductor · High risk Day / 1–4 weeks / 3–12+ months; uncertain positive | $224.58, −0.41%; above 20D $221.90 and 50D $215.62, but Thursday volume only 0.59× average. Counter: yields, China/export controls and AI-ROI scrutiny. | Confirm $225 hold and break $230 with SOX breadth; close below $220 weakens, below $214 invalidates tactical case. Risks: competition, supply, exports, concentration, valuation. | 85 / 78 / 72 |
| 4 IONQ Speculative watch | NYSE · Mid-cap quantum/acquisition mix · Extreme risk Day / 1–4 weeks only; uncertain | $44.98, +5.74% on 1.97× volume; FIU contract and NVIDIA deployment are verified. Counter: 2027/late-2027 installation, undisclosed values, acquisition-heavy economics. | Do not chase; require $43–44 retest hold. Below $41 weakens, below $39 invalidates momentum. Risks: dilution, integration, roadmap, revenue recognition, cash flow, squeezes/reversals. | 87 / 96 / 67 |
| 5 MU Earnings binary | NASDAQ · Large-cap memory · Very high risk Day / 1–4 weeks; uncertain | $1,080.53, +0.81%, +15.1% over 20 sessions; fiscal Q4 results Sept. 30 after close. HBM cycle is catalyst. Counter: extreme expectations and binary guide. | No pre-earnings chase; hold $1,045 and clear $1,100. Below $1,020 invalidates swing. Risks: HBM pricing, margins, capex, cycle, concentration, large earnings gap. | 82 / 94 / 68 |
Bias: sell/chase neither pre-market; favor ANET/NVDA only after U.S. open confirmation and avoid VKTX until supply settles. Biggest risk: durable-goods/yield or Iran headline gap. Invalidation: 10Y falls below 5.12%, NQ holds overnight highs and breadth broadens.
Bias: smaller sizing and cash over long-duration speculation; LLY is the highest-quality catalyst watch, while MU is a binary earnings setup. Biggest risk: 10Y extends above 5.20%. Invalidation: yields stabilize, S&P forms a higher low and AI breadth confirms.
Bias: stage only cash-generative AI/networking/power and clinically validated metabolic leaders; treat quantum/pre-revenue biotech as venture-like. Biggest risk: cash returns fail to outrun the discount rate. Invalidation: estimate cuts, trial/safety failure, financing stress or roadmap slippage.